Celgene backs out of $55M class-action settlement on claims it blocked copycats to Revlimid, Thalomid
admin 9th January 2020 Uncategorised 0Before it closed the Bristol-Myers Squibb merger, Celgene last year inked a $55 million settlement with plaintiffs and payers over allegations it blocked multiple myeloma drug competition. Now, something has changed. The company backed out of the deal in late December, meaning it’ll now have to defend against the class action lawsuit in court.
More: Celgene backs out of M class-action settlement on claims it blocked copycats to Revlimid, Thalomid
Source: fierce